|
1
|
Dong H, Zhu G, Tamada K and Chen L: B7-H1,
a third member of the B7 family, co-stimulates T-cell proliferation
and interleukin-10 secretion. Nat Med. 5:1365–1369. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dong H, Strome SE, Salomao DR, et al:
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential
mechanism of immune evasion. Nat Med. 8:793–800. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hansen JD, Du Pasquier L, Lefranc MP,
Lopez V, Benmansour A and Boudinot P: The B7 family of
immunoregulatory receptors: a comparative and evolutionary
perspective. Mol Immunol. 46:457–472. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Freeman GJ, Long AJ, Iwai Y, et al:
Engagement of the PD-1 immunoinhibitory receptor by a novel B7
family member leads to negative regulation of lymphocyte
activation. J Exp Med. 192:1027–1034. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Konishi J, Yamazaki K, Azuma M, Kinoshita
I, Dosaka-Akita H and Nishimura M: B7-H1 expression on non-small
cell lung cancer cells and its relationship with tumor-infiltrating
lymphocytes and their PD-1 expression. Clin Cancer Res.
10:5094–5100. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wintterle S, Schreiner B, Mitsdoerffer M,
et al: Expression of the B7-related molecule B7-H1 by glioma cells:
a potential mechanism of immune paralysis. Cancer Res.
63:7462–7467. 2003.PubMed/NCBI
|
|
7
|
Ghebeh H, Mohammed S, Al-Omair A, et al:
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in
breast cancer patients with infiltrating ductal carcinoma:
correlation with important high-risk prognostic factors. Neoplasia.
8:190–198. 2006. View Article : Google Scholar
|
|
8
|
Hasan A, Ghebeh H, Lehe C, Ahmad R and
Dermime S: Therapeutic targeting of B7-H1 in breast cancer. Expert
Opin Ther Targets. 15:1211–1225. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Thompson RH, Kuntz SM, Leibovich BC, et
al: Tumor B7-H1 is associated with poor prognosis in renal cell
carcinoma patients with long-term follow-up. Cancer Res.
66:3381–3385. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Iwai Y, Ishida M, Tanaka Y, Okazaki T,
Honjo T and Minato N: Involvement of PD-L1 on tumor cells in the
escape from host immune system and tumor immunotherapy by PD-L1
blockade. Proc Natl Acad Sci USA. 99:12293–12297. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wilcox RA, Feldman AL, Wada DA, et al:
B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell
lymphoproliferative disorders. Blood. 114:2149–2158. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Selenko-Gebauer N, Majdic O, Szekeres A,
et al: B7-H1 (programmed death-1 ligand) on dendritic cells is
involved in the induction and maintenance of T cell anergy. J
Immunol. 170:3637–3644. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fukaya T, Takagi H, Sato Y, et al: Crucial
roles of B7-H1 and B7-DC expressed on mesenteric lymph node
dendritic cells in the generation of antigen-specific
CD4+Foxp3+ regulatory T cells in the
establishment of oral tolerance. Blood. 116:2266–2276. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Luo X, Tarbell KV, Yang H, et al:
Dendritic cells with TGF-beta1 differentiate naive
CD4+CD25− T cells into islet-protective
Foxp3+ regulatory T cells. Proc Natl Acad Sci USA.
104:2821–2826. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yamazaki S, Bonito AJ, Spisek R, Dhodapkar
M, Inaba K and Steinman RM: Dendritic cells are specialized
accessory cells along with TGF− for the differentiation
of Foxp3+ CD4+ regulatory T cells from
peripheral Foxp3 precursors. Blood. 110:4293–4302. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang C, Wu S, Xue X, et al: Antitumor
immunotherapy by blockade of the PD-1/PD-L1 pathway with
recombinant human PD-1-IgV. Cytotherapy. 10:711–719. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dalum I, Jensen MR, Hindersson P, Elsner
HI and Mouritsen S: Breaking of B cell tolerance toward a highly
conserved self protein. J Immunol. 157:4796–4804. 1996.PubMed/NCBI
|
|
18
|
Dalum I, Butler DM, Jensen MR, et al:
Therapeutic antibodies elicited by immunization against TNF-alpha.
Nat Biotechnol. 17:666–669. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xue X, Feng G, Li M, et al: Amelioration
of experimental autoimmune encephalomyelitis by BLyS autovaccine.
Vaccine. 26:2873–2881. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Renard V, Sonderbye L, Ebbehoj K, et al:
HER-2 DNA and protein vaccines containing potent Th cell epitopes
induce distinct protective and therapeutic antitumor responses in
HER-2 transgenic mice. J Immunol. 171:1588–1595. 2003. View Article : Google Scholar
|
|
21
|
Valmori D, Pessi A, Bianchi E and Corradin
G: Use of human universally antigenic tetanus toxin T cell epitopes
as carriers for human vaccination. J Immunol. 149:717–721.
1992.PubMed/NCBI
|
|
22
|
Yu Z, Healy F, Valmori D, Escobar P,
Corradin G and Mach JP: Peptide-antibody conjugates for tumour
therapy: a MHC-class-II-restricted tetanus toxin peptide coupled to
an anti-Ig light chain antibody can induce cytotoxic lysis of a
human B-cell lymphoma by specific CD4 T cells. Int J Cancer.
56:244–248. 1994. View Article : Google Scholar
|
|
23
|
Suh WK, Wang S, Duncan GS, et al:
Generation and characterization of B7-H4/B7S1/B7x-deficient mice.
Mol Cell Biol. 26:6403–6411. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gallina G, Dolcetti L, Serafini P, et al:
Tumors induce a subset of inflammatory monocytes with
immunosuppressive activity on CD8+ T cells. J Clin
Invest. 116:2777–2790. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zang X and Allison JP: The B7 family and
cancer therapy: costimulation and coinhibition. Clin Cancer Res.
13:5271–5279. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Blank C, Kuball J, Voelkl S, et al:
Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell
responses in vitro. Int J Cancer. 119:317–327. 2006. View Article : Google Scholar : PubMed/NCBI
|
